期刊
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE
卷 12, 期 1, 页码 21-32出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.nano.2015.10.005
关键词
Opisthorchis viverrini; Periductal fibrosis; Nanoencapsulated curcumin; Praziquantel; Bile canalicular abnormalities
资金
- Higher Education Research Promotion Group
- National Research University Project of Thailand
- Office of the Higher Education Commission through Health Cluster (SHeP-GMS), Thailand [Ph.D.54203, 1165]
This study investigated the effects of nanoencapsulated curcumin (NEC) and praziquantel (PZQ) treatment on the resolution of periductal fibrosis (PDF) and bile canalicular (BC) abnormalities in Opisthorchis viverrini infected hamsters. Chronic O. viverrini infection (OV) was initially treated with either PZQ (OP) and subsequently treated with NEC (OP + NEC), curcumin (OP + Cur) or unloaded carriers (OP + carrier) daily for one month. OP + NEC treatment reduced the PDF by suppression of fibrotic markers (hydroxyproline content, alpha-SMA, CTGF, fibronectin, collagen I and III), cytokines (TGF-beta and TNF-alpha) and TIMP-1, 2, 3 expression and upregulation of MMP-7, 13 genes. Higher activity of NEC in reducing fibrosis compared to curcumin was also demonstrated in in vitro studies. Moreover, OP + NEC also prevented BC abnormalities and upregulated several genes involved in bile acid metabolism. These results demonstrate that NEC and PZQ treatment reduces PDF and attenuates BC defect in experimental opisthorchiasis. From the Clinical Editor: Infection by Opisthorchis viverrini leads to liver fibrosis and affects population in SE Asia. Currently, praziquantel (PZQ) is the drug of choice but this drug has significant side effects. In this study, the authors combined curcumin (NEC) and praziquantel in a nanocarrier to test the anti-oxidative effect of curcumin in an animal model. The encouraging results may pave a way for better treatment in the future. (C) 2015 Elsevier Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据